tiprankstipranks
Advertisement
Advertisement

HUMA Stock Latest News

Analyst Reiterates Buy on Humacyte, Citing Hemodialysis Upside and KOL Support, Keeps $1 Price Target Unchanged
RatingsAnalyst Reiterates Buy on Humacyte, Citing Hemodialysis Upside and KOL Support, Keeps $1 Price Target Unchanged
6d ago
HUMA
Humacyte Regains Global Rights to Symvess Vascular Graft
PremiumCompany Announcements
Humacyte Regains Global Rights to Symvess Vascular Graft
10d ago
8K
HUMA
Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact
PremiumThe Fly
Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact
10d ago
FMS
HUMA
Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess
PremiumThe Fly
Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess
13d ago
HUMA
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
19d ago
RUM
YSS
Humacyte price target lowered to $1.50 from $3.50 at Barclays
PremiumThe FlyHumacyte price target lowered to $1.50 from $3.50 at Barclays
26d ago
HUMA
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
27d ago
VOD
VST
Humacyte downgraded to Speculative Buy from Buy at Benchmark
Premium
The Fly
Humacyte downgraded to Speculative Buy from Buy at Benchmark
1M ago
HUMA
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
KC
FRO
Humacyte price target lowered to $1 from $3.50 at TD Cowen
PremiumThe Fly
Humacyte price target lowered to $1 from $3.50 at TD Cowen
1M ago
HUMA
Humacyte price target lowered to $1 from $3 at Piper Sandler
PremiumThe Fly
Humacyte price target lowered to $1 from $3 at Piper Sandler
1M ago
HUMA
Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
PremiumRatings
Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
1M ago
HUMA
Morning Movers: AstraZeneca jumps following tozorakimab trial results
PremiumThe FlyMorning Movers: AstraZeneca jumps following tozorakimab trial results
1M ago
AGX
AZN
Humacyte reports Q4 EPS (13c), consensus (14c)
Premium
The Fly
Humacyte reports Q4 EPS (13c), consensus (14c)
1M ago
HUMA
Options Volatility and Implied Earnings Moves Today, March 27, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves Today, March 27, 2026
1M ago
CCL
LGN
HUMA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
HUMA Upcoming Earnings Report: What to Expect?
1M ago
HUMA
Humacyte Announces $20 Million Registered Direct Offering
PremiumCompany Announcements
Humacyte Announces $20 Million Registered Direct Offering
2M ago
8K
HUMA
Humacyte Ends ATM Program, Highlights Symvess Global Expansion
PremiumCompany Announcements
Humacyte Ends ATM Program, Highlights Symvess Global Expansion
2M ago
8K
HUMA
Humacyte prices $20M registered direct offering
PremiumThe Fly
Humacyte prices $20M registered direct offering
2M ago
HUMA
Humacyte receives Symvess purchase commitment
PremiumThe FlyHumacyte receives Symvess purchase commitment
2M ago
HUMA
Humacyte submits MAA for Symvess in Israel for vascular trauma repair
Premium
The Fly
Humacyte submits MAA for Symvess in Israel for vascular trauma repair
2M ago
HUMA
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
SLS
DPRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >